Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment .
New research by Dana-Farber Cancer Institute investigators has encouraging news for young women who have survived breast cancer and want to have children.
Forbes Named These Mass Companies Best Places to Work in U S wupe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wupe.com Daily Mail and Mail on Sunday newspapers.
Investigators at Dana-Farber Cancer Institute have examined the historical evolution of Community Outreach and Engagement initiatives at both the National Cancer Institute (NCI) and National Cancer Institute-Designated Cancer Centers (NCI-DCCs).
A new paper by Dana-Farber Cancer Institute scientists lays the foundation for targeted therapies to inhibit activation of nuclear factor kappa B (NF-κB), a transcription factor that plays a role in various autoimmune and inflammatory diseases and cancers.